Praxis Precision Medicines rises as dual FDA NDA reviews keep catalysts in focus
Praxis Precision Medicines shares are higher as investors continue to price in recent FDA review wins for two late-stage neurology programs. The FDA accepted the ulixacaltamide NDA for essential tremor with a Jan. 29, 2027 PDUFA date and granted priority review for relutrigine with a Sept. 27, 2026 PDUFA date.
1. What’s moving the stock
Praxis Precision Medicines (PRAX) is trading higher on May 1, 2026, as the market continues to build positions around the company’s near- and mid-term regulatory catalysts following two recent FDA milestones: acceptance of the New Drug Application (NDA) for ulixacaltamide hydrochloride in essential tremor and priority review for the NDA of relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies (DEEs). (investors.praxismedicines.com)
2. The key catalysts investors are underwriting
For ulixacaltamide in essential tremor, the FDA accepted the NDA and set a PDUFA target action date of January 29, 2027; the company also said no advisory committee meeting is expected. For relutrigine in SCN2A/SCN8A DEEs, the FDA accepted the NDA for priority review with a PDUFA target action date of September 27, 2026, creating a nearer-term decision point that can drive positioning and volatility into the second half of 2026. (investors.praxismedicines.com)
3. What to watch next
Investors will look for updates on launch-readiness planning for relutrigine ahead of the September 27, 2026 PDUFA date, and for any additional regulatory interactions that could affect ulixacaltamide’s January 29, 2027 review timeline. Separately, Praxis has also flagged additional late-stage and pipeline activity in 2026 that can create incremental headline risk around data presentations and program execution. (investors.praxismedicines.com)